Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ulipristal · 1 trial · 1 indication
Ovulation will be monitored by ultrasound and serum LH and progesterone levels
Ovulation will be monitored by ultrasound and serum LH and progesterone levels
| Arm | Type | Description |
|---|---|---|
| ENG Implant alone | ACTIVE_COMPARATOR | Participants will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion. |
| ENG Implant plus oral UPA | ACTIVE_COMPARATOR | Participants will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion. |
| Name | Type | Description |
|---|---|---|
| ENG implant | DEVICE | This is an FDA-approved contraceptive device |
| oral ulipristal acetate | DRUG | This is an FDA-approved oral emergency contraceptive |
Inclusion Criteria: * Healthy females, age 18-35 * Fluent in English * BMI \< 30 kg/m2 * No known contraindication to either the ENG contraceptive implant or Ulipristal Acetate (UPA) using the CDC Medical Eligibility Criteria for Contraceptive Use 2016 * Not current pregnant and not at risk of preg...
Ulipristal is an investigational small molecule being studied for contraception. It is being developed by Merck & Company, Inc. (MRK) and is currently in Phase 1 clinical development. The drug is intended for use in females aged 18 years and older.
Ulipristal is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for contraception.
Ulipristal is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One early Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
Ulipristal has one completed clinical trial, NCT04291001, titled "Ovarian Function With ENG Implant and UPA Use." This early Phase 1 study enrolled 40 female participants in the United States and was active-controlled, though it was not double-blinded.
Ulipristal is also known by the abbreviation UPA, which was used in the clinical trial title. The drug is being developed by Merck & Company, Inc. for contraception.